Patients with hemophilia will receive high-quality European medicines

Apr 17, 2017

Kyiv, April 17, 2017 – On Monday, April 17, the world is celebrating World Hemophilia Day. Today, up to three thousand people in Ukraine are affected by this life-lasting genetic disorder. It is estimated that only 32% of them will live longer than 50 years. Affecting mostly males, hemophilia is characterized by longer bleeding due to a lack of clotting factor.

On this occasion, the Ministry of Health of Ukraine (MOH) and the United Nations Development Program (UNDP) report the completion of all procurement procedures for adult and child hemophilia medicines according to the agreement.

State budget funds of 130 mln UAH has been allocated under 2016 funds for adult hemophilia, with an additional budget funds of 168 mln UAH for medicines for children with hemophilia type A or B or Willebrand disease. Procurement of adult hemophilia medicines was recently transferred to UNDP, while it is already the second year when UNDP procures child hemophilia.

UNDP managed to achieve child hemophilia prices 7% lower comparing to prices obtained by UNDP last year. In general, more than 22 mln UAH of budget funds savings achieved for both programs will allow to purchase additional amounts of hemophilia medicines. Procured medicines will start arriving to Ukraine in two months – the fastest possible delivery time, considering the sophisticated manufacturing processes due to the biological nature of such products.

Minister of Health a.i. Dr Ulana Suprun commented: “We are changing the Ukrainian health care system for the patients, including those suffering from hemophilia, to receive guaranteed high-quality health services corresponding to international standards. One of these changes - the procurement of medicines through international organizations, which allowed us to avoid corruption and provide high-quality patient essential medicines to patients.”

Janthomas Hiemstra, UNDP Country Director in Ukraine commented: “Reducing premature mortality from non-communicable diseases through prevention and treatment is one of the targets for the SDG global goals, to which all the countries in the world have committed. Having access to quality medicines is key in this process and UNDP is helping Ukraine in getting high quality products for the best price, in a timely manner and through transparent procurement procedures.”

All-Ukrainian Association of Hemophilia highly appreciated the results of the procurement of medicines for hemophilia patients under 2016 funds. The situation with the provision medicines to patients was commented by Oleksandr Shmilo, chairman of the All-Ukrainian Association of Hemophilia: "The process and outcome of tenders for hemophilia medicines correspond to European standards. This is the first tender in Ukraine, which was conducted entirely in the interests of patients with hemophilia."

As of today, UNDP has utilized 1,2 billion UAH for procurement of medicines under the 2016 budget, which constitutes 59% of the funds allocated to the organization. New contracts are signed almost every day as implementation continues.

As for the overall results of medicines procurement under the budget funds of 2016, Ministry of Health reports that 14% of medicines procured with state budget funds of 2016 are already supplied. 52% juvenile rheumatoid arthritis medicines as well as 23% of epidermolysis bullosa medicines are delivered. As well as 72% AIDS medicines which are already in the country. Cystic fibrosis (currently 49%) and other medicines against a range of diseases are in the process of being brought to the country. 99% of tenders are already closed. Evaluation and cost estimate approval are ongoing for other programs.

Background information

Hemophilia is a mostly inherited genetic disorder that impairs the body's ability to make blood clots, a process needed to stop bleeding. There are two main types of hemophilia: hemophilia A, which occurs due to not enough clotting factor VIII, and hemophilia B, which occurs due to not enough clotting factor IX. They are typically inherited from one's parents through an X chromosome with a nonfunctional gene.

In Ukraine (with Crimea and Sevastopol statistics absent) around 1900 adult and 600 child hemophilia patients are registered at the hospitals. 80-90% of children under 14 years old with severe hemophilia become disabled. The same applies to 100% of 18 y.o. patients with severe hemophilia. In Western Europe and North America countries, where preventive treatment of children with hemophilia is implemented, only 1-2% become disabled.

World Hemophilia Day is celebrated since 1989. More information: http://www.worldhemophiliaday.org/

Media inqueries:

Yevgeniy Zelenko, UNDP Ukraine Media Officer | +38 044 254 0035 | yevgeniy.zelenko@undp.org